Cibinqo

Active Ingredient(s): Abrocitinib
FDA Approved: * January 14, 2022
Pharm Company: * PFIZER INC
Category: Skin Care

Abrocitinib, sold under the brand name Cibinqo, is a Janus kinase inhibitor medication used for the treatment of atopic dermatitis (eczema).[2] It was developed by Pfizer.[2] Contents 1 Medical uses 2 Side effects 3 Pharmacology 3.1 Mechanism of action 3.2 Pharmacokinetics 4 History 5 Society and culture 5.1 Legal status 6 References 7 External links Medical uses Abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Cibinqo 50 mg Oral Tablet, Film Coated
NDC: 0069-0235
Labeler:
Pfizer Laboratories Div Pfizer Inc
Cibinqo 100 mg Oral Tablet, Film Coated
NDC: 0069-0335
Labeler:
Pfizer Laboratories Div Pfizer Inc
Cibinqo 200 mg Oral Tablet, Film Coated
NDC: 0069-0435
Labeler:
Pfizer Laboratories Div Pfizer Inc
Cibinqo 50 mg Oral Tablet, Film Coated
NDC: 63539-236
Labeler:
U.S. Pharmaceuticals
Cibinqo 100 mg Oral Tablet, Film Coated
NDC: 63539-336
Labeler:
U.S. Pharmaceuticals
Cibinqo 200 mg Oral Tablet, Film Coated
NDC: 63539-436
Labeler:
U.S. Pharmaceuticals